We are live on ! Find out more
PALI icon

Palisade Bio

5 hedge funds and large institutions have $644K invested in Palisade Bio in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0%0% (-0%)

17% less funds holding

Funds holding: 65 (-1)

19% less capital invested

Capital invested by funds: $791K → $644K (-$147K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
Closed
3
Calls
Puts
Net Calls
Net Calls Change

PALI Hedge Fund Activity: Q4 2019 in Review

5 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2019, worth a combined $644K — down 19% from $791K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of PALI and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, adding an estimated $195K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $183K sold.

  • 5 institutional investors held Palisade Bio (PALI) as of Q4 2019, down from 6 in Q3 2019.
  • Funds reported $644K of Palisade Bio stock for Q4 2019, down 19% quarter-over-quarter.
  • 2 funds opened new Palisade Bio positions in Q4 2019 and 3 closed out, a net change of -1 holder.
  • The largest Palisade Bio buyer in Q4 2019 was Sabby Management, an estimated $195K added.
  • The largest Palisade Bio seller in Q4 2019 was Hudson Bay Capital Management, an estimated $183K sold.

Based on aggregated 13F filings for Q4 2019.